# EDGAR Filing Document

**Accession Number:** 0001287098
**File Stem:** 0001104659-26-074594
**Filing Date:** 2026-6
**Character Count:** 5108
**Document Hash:** cbb35cafe7ed7ca8dbcd5be2ffaaecd2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-074594.hdr.sgml**: 20260616

**ACCESSION NUMBER**: 0001104659-26-074594

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260610

**ITEM INFORMATION**: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

**FILED AS OF DATE**: 20260616

**DATE AS OF CHANGE**: 20260616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MAXCYTE, INC.
- **CENTRAL INDEX KEY:** 0001287098
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 522210438
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40674
- **FILM NUMBER:** 261094923

**BUSINESS ADDRESS:**
- **STREET 1:** 9713 KEY WEST AVENUE,
- **STREET 2:** SUITE 400
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 301-517-5556

**MAIL ADDRESS:**
- **STREET 1:** 9713 KEY WEST AVENUE,
- **STREET 2:** SUITE 400
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MAXCYTE INC
- **DATE OF NAME CHANGE:** 20040415

?xml version='1.0' encoding='ASCII'? MaxCyte, Inc._June 10, 2026

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 10, 2026

**MaxCyte, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40674** | **52-2210438** |
| (State or other jurisdiction of <br>incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **9713 Key West Avenue, Suite 400**<br>**Rockville, Maryland** | **20850** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(301) 944-1700**

**N/A**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading<br>Symbol(s) | Name of each exchange <br>on which registered |
| Common Stock, $0.01 par value | MXCT | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing** 

As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on March 20, 2026, on March 16, 2026, MaxCyte, Inc. (the "Company") received notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") that, because the closing bid price for the Company's common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company did not comply with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1).

On June 10, 2026, the Company received a letter from Nasdaq, notifying the Company that the staff of Nasdaq has determined that for the last 10 consecutive business days, from May 27, 2026 to June 9, 2026, the closing bid price of the Company's common stock has been at $1.00 or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1), and the matter is now closed.

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **MaxCyte, Inc.** | **MaxCyte, Inc.** |
| Date: June 16, 2026 | By: | /s/ Parmeet Ahuja |
|  |  | Parmeet Ahuja |
|  |  | Chief Financial Officer |

---